Primary mitochondrial diseases are characterized by extensive biochemical, clinical, and genetic heterogeneity, making their analysis complex and the diagnostic process very challenging, lengthy, and frustrating. Despite rapid progress in identifying a genetic cause using next-generation sequencing, functional studies showing dysfunction in the mitochondrial respiratory chain are still required in many patients to complete the diagnosis. Current diagnostic practice involves measurement of respiratory chain enzyme activities in muscle or liver biopsies, but these assays do not provide a complete analysis of mitochondrial function and are often avoided due to the invasive nature of the biopsies. Blood sampling and skin biopsy for fibroblast culture are minimally invasive procedures. In recent years, new mitochondrial functional assays were developed in the research setting applicable to fibroblasts or even blood cells opening new opportunities, but the performance in a range of mitochondrial genetic defects and the clinical utility remain unexplored. The goal of this study is to develop functional testing methods and to establish their clinical utility for the diagnosis and confirmation of primary mitochondrial disease in minimally invasive tissue with a focus on skin fibroblasts. We hypothesize that in patients with suspected primary mitochondrial diseases an appropriate panel of tests can be developed and optimized in fibroblasts (or blood cells) with clinical robustness, good sensitivity and specificity, to allow for effective mitochondrial function testing with the strategy dependent on functional category. We will examine a series of mitochondrial functional tests for their diagnostic performance in fibroblasts of patients with known primary mitochondrial diseases, organized by functional class, and determine sensitivity and specificity. Further, we will also examine the effect of differences in tissue culture conditions on the functional test performance in fibroblasts. Environmental factors reflected in culture conditions such as amino acid abundance impact these functions with diagnostic and therapeutic implications. Multiple factors in the functionalization of mitochondrial tRNAs interact with nutritional factors such as amino acids or one-carbon folate esters. In genetic defects of mitochondrial tRNA aminoacyltransferases (ARS2), which interact with the cognate amino acid, increasing the amino acid concentration may improve functionality, whereas decreasing its concentration will exacerbate mitochondrial dysfunction. We will examine the impact of varying the cognate amino acid concentration for tRNA aminoacylation defects on functional assays. The one-carbon charging of intramitochondrial folates affects tRNA processes such as formylation of the initiator methionine by MTFMT, and post transcriptional modification of the wobble base to methyl-uridine or taurinomethyl-uridine in tRNALys and tRNALeu(UUR), which is affected by common pathogenic mutations with disease-causing functional impact. We will evaluate the impact of taurine and of modulation of folate charging by serine or formate.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
2U54NS078059-09
Application #
9804635
Study Section
Special Emphasis Panel (ZTR1)
Project Start
Project End
Budget Start
2019-09-30
Budget End
2020-08-31
Support Year
9
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Columbia University (N.Y.)
Department
Type
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Al-Gadi, Iman S; Haas, Richard H; Falk, Marni J et al. (2018) Endocrine Disorders in Primary Mitochondrial Disease. J Endocr Soc 2:361-373
Hirano, Michio; Emmanuele, Valentina; Quinzii, Catarina M (2018) Emerging therapies for mitochondrial diseases. Essays Biochem 62:467-481
Raghavan, Neha S; Brickman, Adam M; Andrews, Howard et al. (2018) Whole-exome sequencing in 20,197 persons for rare variants in Alzheimer's disease. Ann Clin Transl Neurol 5:832-842
Barca, Emanuele; Ganetzky, Rebecca D; Potluri, Prasanth et al. (2018) USMG5 Ashkenazi Jewish founder mutation impairs mitochondrial complex V dimerization and ATP synthesis. Hum Mol Genet 27:3305-3312
Shen, Lishuang; Attimonelli, Marcella; Bai, Renkui et al. (2018) MSeqDR mvTool: A mitochondrial DNA Web and API resource for comprehensive variant annotation, universal nomenclature collation, and reference genome conversion. Hum Mutat 39:806-810
Garone, Caterina; Taylor, Robert W; Nascimento, Andrés et al. (2018) Retrospective natural history of thymidine kinase 2 deficiency. J Med Genet 55:515-521
Winawer, Melodie R; Griffin, Nicole G; Samanamud, Jorge et al. (2018) Somatic SLC35A2 variants in the brain are associated with intractable neocortical epilepsy. Ann Neurol 83:1133-1146
Zolkipli-Cunningham, Zarazuela; Xiao, Rui; Stoddart, Amy et al. (2018) Mitochondrial disease patient motivations and barriers to participate in clinical trials. PLoS One 13:e0197513
Huang, Xiaoping; Bedoyan, Jirair K; Demirbas, Didem et al. (2017) Succinyl-CoA synthetase (SUCLA2) deficiency in two siblings with impaired activity of other mitochondrial oxidative enzymes in skeletal muscle without mitochondrial DNA depletion. Mol Genet Metab 120:213-222
Mancuso, Michelangelo; McFarland, Robert; Klopstock, Thomas et al. (2017) International Workshop:: Outcome measures and clinical trial readiness in primary mitochondrial myopathies in children and adults. Consensus recommendations. 16-18 November 2016, Rome, Italy. Neuromuscul Disord 27:1126-1137

Showing the most recent 10 out of 49 publications